On 9 November 2026, Celltrion announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an expanded indication for Steqeyma®, biosimilar to Janssen’s Stelara® (ustekinumab), to treat Crohn’s disease and ulcerative colitis in children aged two and older.
Steqeyma® is already approved in Europe for Crohn’s disease in paediatric patients weighing at least 40 kilograms, as well as for adult Crohn’s disease and ulcerative colitis. It is also approved for plaque psoriasis in adults and children and psoriatic arthritis in adults.
Celltrion has launched Steqeyma® in Europe (November 2024), the US (March 2025), Japan (July 2025) and Australia (listed on the PBS from 1 August 2025).
